Mosaic Biosciences

Mosaic Biosciences

Biotechnology company developing synthetic materials for native tissue regeneration and tissue engineering platforms

Mosaic Biosciences is a biotechnology company based in Colorado producing a new type of synthetic biomaterial based on thiol-ene chemistry to help in drug delivery and native tissue regeneration. The technology is based on thiol-ene click chemistry and modular polymer platform. It is used for drug delivery, regenerative medicine, stem cell therapies, and sealant and adhesion barriers.

Product

The biomaterial developed by Masoaic’s thiol-ene chemistry has many applications while being safe, fast and controllable. It does not react with the body chemistry of the patient, is pH-independent, and not inhibited by oxygen. The non-reactive structure of the biomaterial polymer makes it ideal for drug delivery. Photo-initiation allows for spatial and temporal control of reactions while network structures and material properties can be controlled with the use of click chemistry reactions.

The biomaterials can use or encapsulate proteins, nucleic acids, and cells which makes them act as a bioactive material to initiate a biological response from the body. Mosaic’s technology can use synthetic components like PEG (Polyethylene Glycol) and PLGA (Poly Lactic-co-Glycolic Acid) or natural components like proteins, peptides, hyaluronic acid, and nucleic acids to create biomaterials. The biomaterials created using the technology can have a bioresponsive degradation mechanism and can quickly be cleared from the body.

History

Pete Mariner founded the company in 2009 and is the Director of Wound Healing as of March 2019. The company’s team primarily consists of polymer chemists, protein and nucleic acid biochemists, and biologists. The company is headquartered in Boulder, Colorado.

Timeline

October 24, 2017

Catalyst Biosciences and Mosaic Biosciences Partner on Eye Disorder Therapeutics

The two companies partnered to develop anti-complement component 3 (C3) proteases from Catalyst for dry age-related macular degeneration (dAMD) and other serious inflammatory retinal disorders.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Mosaic Biosciences Series A round
1,000,000
November 8, 2011
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Daniel Rassiner

Employee

Diana Ngo

Employee

Dr. Eric Furfine

Ophthalmology

Martin Stanton

Chief Executive Officer

Pete Mariner

Founder

Peter Mariner

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.